Leading Element Driving Change in the Cancer Cachexia Market in 2025: Impact Of Cancer Prevalence On The Cancer Cachexia Market Driver

What Is the Estimated Market Size and Growth Rate for the Cancer Cachexia Market?
The market for cancer cachexia has experienced solid growth of late. This growth will continue, with the market size projected to increase from $2.47 billion in 2024 to $2.62 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.4%. The past period of growth can be traced back to the advancements in our understanding of the biology of cancer, the frequency of cancer, the rise in the elderly population, increased emphasis on patient-focused care, the expansion of treatment alternatives, and heightened awareness among medical practitioners.

Expectations are high for the cancer cachexia market to experience robust growth in the forthcoming years. The market is projected to reach $3.33 billion by 2029, increasing at a 6.2% compound annual growth rate (CAGR). This anticipated growth in the forecast period is linked to expanding understanding of cachexia management, an aging population, increasing adoption of innovative treatment methods, growing healthcare spending and supportive government policies. Key trends during the forecast period comprise heightening research and development activities, broadening therapeutic alternatives, enhanced diagnosis frequencies, adoption of new treatment modalities, and progress in care management strategies.

What Factors Are Propelling the Expansion of the Cancer Cachexia Market?
The growth of the cancer cachexia market is anticipated to be driven by the rapid rise in cancer cases. Cancer, a disease characterised by uncontrolled multiplication of abnormal cells forming tumours and disrupting typical body functions, is triggered by multiple elements including lifestyle shifts, ecological impacts, an ageing demographic, genetic susceptibility, enhanced diagnostic techniques facilitating early detection, and heightened awareness that encourages individuals to pursue medical care. Improved medical technology and a wider comprehension of cancer and its consequent complications are leading to an increase in the diagnosis and reporting of cancer cachexia. Simultaneously, healthcare professionals are honing their skills to recognise symptoms of cachexia, aiding in prompt treatment initiation. To illustrate, the Australian Bureau of Statistics announced in December 2023 that approximately 1.8% of the Australian population, equating to 456,200 people, had been diagnosed with cancer in 2022. Moreover, the US-based National Cancer Institute projected in May 2024 that there would be 2,001,140 new cancer cases in the U.S in 2024, leading to about 611,720 fatalities. Globally, nearly 20 million new cancer cases and 9.7 million cancer-related deaths were documented in 2022. By 2040, it is projected that the number of new cancer cases per annum will escalate to 29.9 million and cancer-related deaths will reach 15.3 million. Hence, the swelling prevalence of cancer is fuelling the expansion of the cancer cachexia market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

Who Are the Dominant Companies Influencing Cancer Cachexia Market Trends?
Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

How Is the Cancer Cachexia Market Evolving?
Leading companies engaged in the cancer cachexia market are focusing on the invention of advanced medicines, like monoclonal antibodies for cachexia, with the aim of crafting a customised treatment for cancer cachexia. These specialized treatments are designed to enhance body weight, muscle mass, and overall life quality for patients suffering from the condition. A monoclonal antibody for cachexia specifically targets and curbs elements that trigger muscle and weight loss. For example, in September 2024, the American pharmaceutical firm, Pfizer Inc., reported successful outcomes from its Phase 2 trial for Ponsegromab, a monoclonal antibody designed to target GDF-15, in patients battling cancer cachexia. The study established a notable rise in body weight and muscle mass, as well as enhancements in appetite and physical activity levels, with the most significant results observed with the 400 mg dose. Bolstered by these promising results, Pfizer plans to commence registration-directed studies in 2025 to delve deeper into the potential of Ponsegromab in treating cancer cachexia.

What Are the Different Segmentations in the Cancer Cachexia Market?
The cancer cachexia market covered in this report is segmented -

1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics
2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions
3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies

Subsegments:
1) By Progestogens: Megestrol Acetate, Medroxyprogesterone Acetate, Hydroxyprogesterone Caproate
2) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone
3) By Combination Therapies: Progestogens + Corticosteroids, Progestogens + Anabolic Agents, Corticosteroids + Anabolic Agents
4) By Other Therapeutics: Anabolic Agents, Appetite Stimulants, Anti-inflammatory Drugs, Nutritional Supplements

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

Which Region Is at the Forefront of the Cancer Cachexia Market?
North America was the largest region in the cancer cachexia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Cancer Cachexia Global Market Report?

- Market Size Analysis: Analyze the Cancer Cachexia Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Cancer Cachexia Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Cancer Cachexia Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Cancer Cachexia Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15527

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.